



PREDICT S.p.A.

Investor Presentation

October 2026



AT A GLANCE

Hi-Tech solutions for advanced diagnostics

Predict S.p.A., based in Bari, is an innovative SME active in the med-tech sector, specializing in non-invasive in vivo diagnostics. It markets medical imaging systems for screening, providing technical assistance, and develops innovative technologies in the fields of ***breath analysis*** and ***digital healthcare***.


4 Strategic Business Units

Imaging

Distribution of **diagnostic equipment** (for ultrasound, X-rays, and magnetic resonance imaging). Training of healthcare personnel.

People Support

Technical assistance and after-sales services, maintenance, repair, and add-ons. **Predictive healthcare** and hospital **disinfection solutions**.



€0.84mm
invested in
R&D
in 2025

~20 years
of partnership
with GE
HealthCare

3
patents

33
Highly
qualified
employees*

*As of 30/06/2026

Mistral

Development and sale of advanced **breath analysis** solutions for the early screening of diseases.



Digital Healthcare

Development and sale of **innovative** solutions in augmented reality, holography, and collaborative **robotics** to improve healthcare services.



Traditional

Innovative

MILESTONES

2008
**PREDICT WAS
FOUNDED**

2008

SUBSCRIPTION
OF AGENCY
MANDATE FOR
GE

START-UP

2012

AFTER-SALES
SERVICES FOR
GE
MACHINERY

**2016
2018**

MISTRAL,
OPTIP &
APHEL
DEVELOPING

RESEARCH AND DEVELOPMENT

DELIVERY OF
FIRST
SAMPLER

2020

FIRST
ROBOT
INSTALLATION

2021

2023

OPTIP
STAGE AND
MISTRAL
LAB

CONSOLIDATION AND INNOVATION

2024

INNOVATIVE
SME
AND IPO ON
EGM

2025

NEW OFFICES
OPENING OUT
| TEAM EXPANSION

DISTRIBUTION AGREEMENTS

Shenzhen Spinq | Airc Medical EU | UVC Solutions
| Caresmed

ORDERS/CONTRACTS

2 Mistral Samplers+services (IRCCS Bari) | MQ
Analyzer (DIF Bari) | 2 Mistral Samplers PoliBA | 3
Robots Corporea Museum (NA) | LiberAUT Project
| RTI Tender «AMiCa» | Fetal ultrasound «IAUSO» |
Exprivia RTI Tender ICT services «InnovaPuglia»

CALLS

PNRR S4D Precision Diagnostic | PNC D3-4Health

TRIALS

EMICENTER Project | ASMA Trial (Foggia) | Head-
neck cancer study (IFO Roma)

2026

AGREEMENTS

- Weatecho (Hospital 4.0)
- Robocore Technology
- GE HealthCare renewal
- Luso Electronics (UK, breath analysis)

ORDERS/CONTRACTS

- Niguarda tele-ultrasound platform, OPTIP Bodycam for ASL Foggia, 11 ultrasound scanners for ASL BAT, Hermes Robot for Casa Solievo della Sofferenza

CALL&TRIALS

- Studies: Mistral occupational medicine (automotive) at **COM** (MI), **RECAP** at Sant'Orsola Bologna, pediatric tele-ultrasound at Buzzi (MI)
- **PIA** Project (**C.U.R.E.S.**)
 - **STEP** (R.E.S.P.I.R.A) tender

INDUSTRY BUSINESS SYSTEM AND BUSINESS MODEL

Predict offers a model based on the supply of innovative and high-tech solutions for the healthcare sector, ensuring a favorable ecosystem for widespread technological innovation processes.



4

Strategic Business Units

Imaging	Mistral
People Support	Digital Healthcare
2 SBU with established solutions to provide stable & recurring revenues	2 SBU with innovative solutions in growing markets
DISRUPTIVE INNOVATION HI-TECH IN THE HEALTHCARE WORLD	

The Predict model enables a balanced and efficient management of resources and innovation:

- Each **SBU** has a structured management control system.
- Investments in innovation are planned considering the SBUs and their impact on the business.


STRATEGIC BUSINESS UNITS

The activities of Predict are divided into 4 Strategic Business Units:


SBU	Traditional		Innovative	
	Imaging	People Support	Mistral	Digital Healthcare
Activity description	• Sale of medical imaging equipment*, marketed in the field of in vivo diagnostic imaging. • Distribution agreements with GE HealthCare, Fora S.p.A. and Caresmed S.r.l. • Solutions: ultrasound systems, X-ray, CT, MRI, PET, mobile units rental services, densitometers and bioimpedance meters • Med-tech education and training * new/used, for private customers only	• Technical support for the installed imaging equipment (installations, calibrations, electrical safety checks) and repair (for innovative SBUs) • Sales of spare parts and add-ons • Predictive Healthcare Solutions MRI (AI) • Solutions for the disinfection of hospital environments	• Development, design & commercialization of screening solutions based on proprietary technology for breath analysis: Mistral Sampler for VOC sampling, Mistral Analytics for medical history. • Owned Mistral Lab and the construction of "turnkey" breath analysis laboratories for polyclinics, IRCCS, CRC • Clinical trials and prototypes • Research partnerships with universities to evolve and integrate technologies	• Development and sale of solutions based on remote communication through augmented reality (Optip) and robotics (Aphel), also on active ageing (home robotics services) • Optip: Interaction in holographic presence (AR, VR, MR technologies). Holographic stages for training and education. • Aphel: AI platform that integrates humanoid and collaborative robots • Commercialization of Quantum computers in the education & healthcare sector
KPIs	Revenue FY25 71% → € 5.4 mn 1H26 78% → € 3.1 mn	Revenue FY25 15% → € 1.2 mn 1H26 16% → € 0.7 mn	Revenue FY25 3% → € 0.2 mn 1H26 0.3% → € 0.01 mn	Revenue FY25 11% → € 0.8 mn 1H26 5% → € 0.2 mn
			Sample collectors: 	

PRODUCTS AND APPLICATION PORTFOLIO

Predict is unique on the national scene, ensuring technological oversight of health data collected through medical devices and the developed equipment.



SYNERGIES BETWEEN THE DIFFERENT SBUs



VALUE CHAIN AND BUSINESS PROCESS

Predict sells its products both through direct orders from private customers and through bids open to public and private entities.



SUPPLIERS AND CLIENTS

SUPPLIERS

- ✓ Manufacturers of Imaging Equipment
- ✓ Companies providing in vivo diagnostic Imaging services
- ✓ Manufacturers of systems for gas chromatography and mass spectrometry analysis
- ✓ Players in the hospital disinfection sector through ultraviolet radiation
- ✓ Manufacturers of humanoid robots and collaborative robots
- ✓ Manufacturers of augmented reality headsets
- ✓ Software & Hardware companies

CLIENTS

PUBLIC:

- ✓ university clinics
- ✓ IRCCS
- ✓ Public Hospitals
- ✓ Universities
- ✓ Primary and Secondary Schools

PRIVATE:

- ✓ Hospitals
- ✓ Clinics
- ✓ Specialized outpatient centers
- ✓ Specialized medical practices
- ✓ Insurance companies
- ✓ Healthcare professionals
- ✓ Analysis Laboratories
- ✓ Hi-tech healthcare companies

R&D VALIDATION



RESEARCH AND DEVELOPMENT

R&D

Partnership
with hospitals,
IRCCS, universities

Investments
2019-1H26
€ 5.4mn~

MISTRAL

- **2016-22:** completed breath sample collection system (Mistral Sampler) and CE mark. In 4Q21-1H22 Mistral Lab breath analysis laboratory built and launched. In 3Q22 Process automation of the Lab's examination procedures
- **FY23:** AI algorithms have been defined to perform automatic analysis (Mistral AI) on breath samples. Multicentric clinical trials have been initiated for validation on prostate cancer
- **FY24:** Qualitative and semi-quantitative identification of a set of molecules representative of the pathologies investigated; start of clinical trials for other studies
- **FY25:** Clinical trials on asthma, pilot study on head and neck cancers, development of AI-based and machine learning algorithms for major cancers (colorectal, lung, prostate, breast), integration of advanced QEPAS sensors, management software testing
- **2026:** asthma trial completed; development of disease-specific AI algorithms and of a portable sampler; start of the STEP project (R.E.S.P.I.R.A., 36 months); 4 patents by year-end



DIGITAL HEALTHCARE

- **2017-20:** Optip solution developed based on the HoloLens AR headset, AI platform implemented for Ubtech robot, now known as 'Aphel Helios'. Temi robot integrated into the Aphel platform, now known as 'Aphel Hermes'
- **2020-23:** The first ABB collaborative robot has been integrated into the Aphel family, now known as 'Aphel Kronos'
- **FY23-24:** Developed the 'Optip Stage' solution (holograms without a headset). AI-based project to guide ultrasound technicians. In 2024 Launched project for a robotic system for remote ultrasound; integration of collaborative robotics, computer vision, and deep learning.
- **FY25:** Feedback from ultrasound system installations, AI-assisted box platforms, launch of bodycams in Emergency Departments and ambulance services, introduction of Aphel Alpha Mini, start of the CURES research project
- **2026:** Optip Nuva (AI-assisted ultrasound); pediatric tele-ultrasound at Buzzi Hospital; continuation of CURES (robotics + ultrasound); joint patent filing with UniBA under evaluation



Co-financing for innovation

PIA

Smart Diagnostic System

Contribution: €2.02mn
Period: 10/2021-12/2024

D3-4HEALTH

(Endoscope Project)

Contribution: €266k
Period: 10/2024-04/2026

HEAL ITALIA

Contribution: €212k
Period: 08/2024-11/2025

PIA C.U.R.E.S.

Contribution: TBC
Start: 10/2025

STEP R.E.S.P.I.R.A.

Contribution: TBC
Start: 07/2026

PATENTS AND CE TRADEMARKS

OPTIP

08/2017

Filing of European patent application

12/2019

Filing of CE trademark

09/2021

Patent granted in the USA,
no. 11,122,164 B2

12/2025

Filing of Italian patent application for Optip Nuva

08/2018

Filing of international PCT patent application

02/2020

Filing of CE trademark for the new product release

03/2023

Utility model granted in Italy no.
202023000000231

2026

European patent extension for Optip Nuva

12/2018

Filing of International PCT patent application, converted into European patent application no. EP3873347

02/2019

Filing of CE trademark

02/2022

Patent granted and validated in: Spain; Switzerland; Austria; United Kingdom; Germany; Netherlands; France; Italy

10/2025

Filing of a **patent** application for a sampler with real-time VOCs analysis

2026


4 Breath analysis technologies patents to be filed by year-end

Mistral
INSIDE THE BREATH


REFERENCE MARKETS AND DRIVERS

Predict operates in 3 market niches in the Healthcare sector, growing globally:


1 Imaging



2 Breath analysis



3 Digital Health Tech



The ultrasound market in Italy in 2023 was estimated by **COCIR** at **€180 mn**. GE HealthCare has an estimated market share of around 24%, with Predict being the exclusive distributor in Puglia. 42% market share of the market in Apulia estimated for Predict.

Trend: **increase in the demand** for Breath Analysis services as a tool for screening oncological diseases, thanks to the use of **non-invasive** breath biopsy technologies.

Over **€12 billion** from the **PNRR** allocated to **personnel training** with technologies for **efficiency improvements**, aimed at addressing the staff shortage in the **SSN**

D
r
i
v
e
r

- ✓ Increase in life expectancy
- ✓ Obsolescence of equipment, productivity improvement
- ✓ Growth of private and accredited facilities offering diagnostic services
- ✓ Expansion of equipment usage opportunities (territories and diagnostic fields)

- ✓ Statistical increase in affected diseases
- ✓ Higher demand for non-invasive techniques
- ✓ High degree of accuracy compared to traditional screening (biomarkers)
- ✓ Versatility of the methodology that enables the optimization of healthcare spending and expansion into unexplored areas

- ✓ Need for digital alternative medicine solutions
- ✓ Decrease in the number of healthcare workers
- ✓ Opportunities for new services provided through the combination of medicine and technology
- ✓ New teaching methods to accelerate medical training

MANAGEMENT TEAM & KEY PEOPLE



Angelo Gigante

Founder, President, CEO

20+ years of experience

2008: founds Predict
2003-2007: sales in GE HealthCare
2000-2003: R&D as Consultant Engineer, software designer
Master's Degree in Electronic Engineering at PoliBa



Isabella Cafagna

Vice President and CEO

Director SBU Mistral, SBU Digital Healthcare

10+ years of experience

2015-today: Sales Account Manager, Sales Manager, SBU Mistral Director for Predict
Master's Degree in Chemistry at UniBa
PhD in Environmental Engineering and Chemistry PoliBa



Loredana Amoruso

CEO

Tender and Legal Affairs Manager

10+ years of experience

2015-today: public tender specialist, legal affair, Legal Department Manager, Tenders Office, Trademarks and Patents for Predict
2009: Registered with the Bar Association of Bari
Master's degree in Law UniBa



Angelo Ceci

Chief Financial Officer and
Investor Relations Manager

3+ years of experience

2023: Joins Predict in Finance & Control
Degree in Economics and Management,
University of Trento



Giuseppe Carella

Director, Special Attorney
Director SBU Imaging

10+ years of experience

2014-today: Technical Assistance, Sales for Services, SBU People Support Service Manager, SBU Imaging Sales Manager
2024: Board Member of Predict
Master's degree in Chemistry, UniBa



Daniele Volpicella


Service Manager
SBU People Support

9 years of experience

2016: SBU Imaging Sales Manager 2024: SBU People Support Service Manager Diploma in Industrial Technical Expert with specialization in Electrical Engineering and Automation

SHAREHOLDING AND GOVERNANCE

SHAREHOLDING



Data updated as of 9th July 2026

*% on the total shares.

- Qo3 S.r.l.: 76.47% of total shares | 69.01% ordinary shares | 83.94% voting rights
- Treasury shares: 0.62% of total shares | 0.82% ordinary shares | 0.42% voting rights
- Other shareholders**: 0.62% of total shares | 0.82% ordinary shares | 0.42% voting rights
- Market (float): 22.29% of total shares | 30.18% ordinary shares | 15.63% voting rights

** Other shareholders subject to lock-up restrictions. The lock-up has been lifted solely with respect to the future tranches of the Plan; the 48,000 shares relating to the 2025 tranche, credited on 6 July 2026, remain subject to the original 30-month lock-up period.



GOVERNANCE

Board of Directors**

Angelo Aurelio Gigante <i>President and CEO</i>	
Isabella Cafagna <i>Vice President, Executive Director</i>	Loredana Amoruso <i>Executive Director</i>
Rocco Dichio <i>Director</i>	Valeria Stucci <i>Director</i>
Giuseppe Carella <i>Director, Special Attorney</i>	Vito Anelli <i>Independent Director</i>

Board of Statutory Auditors**

- ⌚ President: F. Sanseverino
- ⌚ Statutory Auditor: R. Pierno
- ⌚ Statutory Auditor: M. T. Rizzi
- ⌚ Alternate Statutory Auditor: M. Secchi
- ⌚ Alternate Statutory Auditor: V. Virzi

Supervisory Committee

- ⌚ President: Atty. F. Di Marzio
- ⌚ Atty. E. De Tommaso
- ⌚ Atty. S. Pellegrino

Audit Firm***



Sustainability Report



**REPORT DI
SOSTENIBILITÀ 2025**

**In office until the approval of the financial statements as of 31/12/2026
 ***In office until the approval of the financial statements as of 31/12/2027

Approved by the BoDs on March 23, 2026

E

Scope 1 Emissions

65 tCO₂e tot. | 2.4 tCO₂e per FTE

Scope 2 Emissions

14.1 tCO₂e tot. | 0.52 tCO₂e per FTE

Energy Efficiency

Building energy class improved from F to A1

Procurement

Adoption of the **Sustainable Procurement Manual**

Waste

Ongoing agreement with a **local company for special waste treatment**

S

Production Bonuses

Implementation of a **PDR** linked to the **achievement** of **EBITDA-related objectives**

Corporate Welfare

Internal events (Predict Kick-off, team building Sunset Party, Summer Race) and flexible work policies

Childcare Project

Donation of innovative equipment to **associations and schools**

Employee Training

Mandatory **training courses** conducted by the Palo Alto School

G

Gender Equality Committee

40% Male Employees
60% Female Employees

ESG Committee

Key people involved in defining **ESG goals** and drafting the **Sustainability Report**

Code of Ethics and Legislative Decree 231

Updated to reflect new transparency and accountability requirements

Stakeholder Engagement

Adoption of **engagement policies** on sustainability topics

Certifications



GROWTH STRATEGIES

Internal growth

Development of innovative SBUs with a focus on Mistral

- R&D, partnerships with clinical research centers and university TTOs
- Hiring of new professional roles, strengthening of commercial functions, and product development
- Roll-out of a network of Mistral Labs in Italy
- Development of partnership agreements with pharmaceutical companies

Expansion of the hi-tech solutions offering

- Consolidation of the leadership position in the offering of hi-tech solutions through the expansion of the product range and the provision of training courses

Strengthening of traditional SBUs and cross-selling

- Diversification of product types, differentiating suppliers, and expanding the geographic markets served.
- Development of internal synergies to increase cross-selling activities between products and services to enhance customer loyalty and improve profitability


External growth

M&A


- Evaluation of potential acquisitions in breath analysis and digital healthcare to gain complementary know-how and expand market share

FINANCIAL HIGHLIGHTS 1H26


Revenue / VoP (€mn)




EBITDA (€mn)




Net Result (€mn)



NFI / NFI Adj.* (€mn)



Equity (€mn)



1H26 vs 1H25 INCOME STATEMENT

Reclassified Income Statement (Euro/000)	30.06.2026	% ^(*)	30.06.2025	% ^(*)	Var. %
Sales Revenues	4,014	100.0%	2,400	100.0%	67.3%
Increases in fixed assets for internal work	311	7.7%	-	0.0%	n/a
Other revenues and income	331	8.2%	247	10.3%	34.0%
Value of Production	4,656	116.0%	2,647	110.3%	75.9%
Costs of raw materials, components, consumption and merchandise	(2,342)	-58.3%	(1,276)	-53.2%	83.5%
Cost of services	(876)	-21.8%	(752)	-31.3%	16.5%
Use of third-party assets	(123)	-3.1%	(66)	-2.8%	86.4%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	(152)	-3.8%	(139)	-5.8%	9.4%
Personnel Expenses	(751)	-18.7%	(677)	-28.2%	10.9%
Other operating expenses	(18)	-0.4%	(10)	-0.4%	80.0%
EBITDA **	395	9.8%	(273)	-11.4%	> 100.0%
Depreciations and write-downs	(396)	-9.9%	(154)	-6.4%	> 100.0%
EBIT ***	(1)	0.0%	(426)	-17.8%	-99.8%
Financial income	1	0.0%	(18)	-0.7%	> 100.0%
EBT ****	(1)	0.0%	(444)	-18.5%	-99.8%
Income taxes	-	0.0%	-	0.0%	n/a
Net Result	(1)	0.0%	(444)	-18.5%	-99.8%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

(***) EBIT represents the result before income taxes and financial income and charges. EBIT therefore represents the result of operating activities before the remuneration of both third-party and own capital. EBIT is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBIT is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

(****) EBT represents the result before income taxes and deferred taxation.

1H26 vs 1H25 SBU INCOME STATEMENT

Imaging

SBU Imaging Income Statement (Data in Euro/000)	30.06.2026	% ^(*)	30.06.2025	% ^(*)	Var. % 1H26-1H25
Sales Revenues	3,149	100.0%	1,789	100.0%	76.0%
Increases in fixed assets	–	0.0%	–	0.0%	n/a
Other revenues and income	60	1.9%	40	2,3%	50.0%
Value of Production	3,208	101.9%	1,829	102.3%	75.4%
Costs of raw materials, components, consumption and merchandise	(1,983)	-63.0%	(883)	-49.3%	> 100.0%
Cost of services	(239)	-7.6%	(238)	-13.3%	0.4%
Use of third-party assets	(33)	-1.0%	(17)	-0.9%	94.1%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	(187)	-5.9%	(210)	-11.7%	-11.0%
Personnel Expenses	(156)	-4.9%	(145)	-8.1%	7.6%
Other operating expenses	(7)	-0.2%	(3)	-0.2%	> 100.0%
EBITDA**	605	19.2%	335	18.7%	80.6%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

1H26 vs 1H25 SBU INCOME STATEMENT

People Support

SBU People Support Income Statement (Data in Euro/000)	30.06.2026	% ^(*)	30.06.2025	% ^(*)	Var. % 1H26-1H25
Sales Revenues	655	100.0%	502	100.0%	30.5%
Increases in fixed assets	–	0.0%	–	0.0%	n/a
Other revenues and income	15	2.2%	12	2.3%	25.0%
Value of Production	670	102.2%	513	102.3%	30.6%
Costs of raw materials, components, consumption and merchandise	(224)	-34.2%	(268)	-53.3%	-16.4%
Cost of services	(96)	-14.6%	(91)	-18.1%	5.5%
Use of third-party assets	(21)	-3.2%	(8)	-1.7%	>100.0%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	9	1.4%	23	4.5%	-60.9%
Personnel Expenses	(112)	-17.1%	(101)	-20.2%	10.9%
Other operating expenses	(3)	-0.4%	(2)	-0.3%	50.0%
EBITDA **	223	34.1%	66	13.2%	>100.0%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

1H26 vs 1H25 SBU INCOME STATEMENT

Mistral

SBU Mistral Income Statement (Data in Euro/000)	30.06.2026	%^(*)	30.06.2025	%^(*)	Var. % 1H26-1H25
Sales Revenues	13	100.0%	19	100.0%	-31.6%
Increases in fixed assets	193	n/a	–	0.0%	n/a
Other revenues and income	73	n/a	192	n/a	-62.0%
Value of Production	278	n/a	212	n/a	31.1%
Costs of raw materials, components, consumption and merchandise	(55)	n/a	(52)	n/a	5.8%
Cost of services	(192)	n/a	(222)	n/a	-13.5%
Use of third-party assets	(23)	n/a	(19)	-97.8%	21.1%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	6	44.2%	11	56.1%	-45.5%
Personnel Expenses	(263)	n/a	(258)	n/a	1.9%
Other operating expenses	(4)	-32.5%	(3)	-15.5%	33.3%
EBITDA **	(253)	n/a	(332)	n/a	-23.8%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

1H26 vs 1H25 SBU INCOME STATEMENT

Digital Healthcare

SBU Digital Healthcare Income Statement (Data in Euro/000)	30.06.2026	% ^(*)	30.06.2025	% ^(*)	Var. % 1H26-1H25
Sales Revenues	198	100.0%	90	100.0%	> 100.0%
Increases in fixed assets	118	59.6%	–	0.0%	n/a
Other revenues and income	184	93.0%	3	3.2%	> 100.0%
Value of Production	499	n/a	93	103.2%	> 100.0%
Costs of raw materials, components, consumption and merchandise	(80)	-40.4%	(73)	-81.4%	9.6%
Cost of services	(350)	n/a	(202)	n/a	73.3%
Use of third-party assets	(46)	-23.1%	(22)	-24.6%	> 100.0%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	20	10.3%	38	42.0%	-47.4%
Personnel Expenses	(220)	n/a	(173)	n/a	27.2%
Other operating expenses	(4)	-2.3%	(2)	-2.5%	100.0%
EBITDA **	(180)	-91.2%	(341)	n/a	-47.2%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.


1H26 vs FY25 BALANCE SHEET

Riclassified Balance Sheet (Euro/000)	30.06.2026	% ^(*)	31.12.2025	% ^(*)	Var. % 1H26-FY25
Intangible fixed assets	1,128	32.9%	1,052	41.5%	7.2%
Tangible fixed assets	465	13.6%	534	21.1%	-12.9%
Financial fixed assets	711	20.8%	702	27.7%	1.3%
Net fixed assets **	2,304	67.2%	2,289	90.3%	0.7%
Inventory	809	23.6%	943	37.2%	-14.2%
Trade receivables	2,183	63.7%	2,154	85.0%	1.3%
Trade payables	(2,106)	-61.5%	(2,487)	-98.1%	-15.3%
Trade working capital	886	25.9%	611	24.1%	45.0%
Other current assets	1,494	43.6%	1,314	51.8%	13.7%
Other current liabilities	(1,020)	-29.8%	(1,605)	-63.3%	-36.4%
Net Tax receivables and payables	269	7.8%	453	17.9%	-40.6%
Accruals and deferred income	(243)	-7.1%	(296)	-11.7%	-17.9%
Net working capital ***	1,386	40.5%	478	18.8%	>100.0%
Termination indemnity/severance pay	(241)	-7.0%	(209)	-8.3%	15.3%
Provisions for risks and charges	(22)	-0.7%	(22)	-0.9%	-
Net Invested Capital ****	3,426	100.0%	2,535	100.0%	35.1%
Loans from banks	-	-	-	-	n/a
Other current financial assets	-	-	-	-	n/a
Cash and cash equivalents	(949)	-27.7%	(1,840)	-72.6%	-48.4%
Net financial Indebtedness *****	(949)	-27.7%	(1,840)	-72.6%	-48.4%
Integrated Incentive Program (PIA) contribution	(202)	-5.9%	(202)	-8.0%	-
Net financial Indebtedness Adjusted	(1,151)	-33.6%	(2,041)	-80.5%	-43.6%
Share capital	135	3.9%	135	5.3%	-
Reserves and retained earnings	2,752	80.3%	2,580	101.8%	6.7%
Share Premium Reserve	1,489	43.5%	1,489	58.7%	-
Net result	(1)	-0.0%	171	6.7%	<-100.0%
Equity	4,375	127.7%	4,375	172.6%	-
Total sources	3,426	100.0%	2,535	100.0%	35.1%

(*) Percentage incidences calculated on Net Working Capital, deferred/anticipated items and other non-current assets. (**) Net Fixed Assets is calculated as intangible, tangible and financial fixed assets. (***) Net Working Capital is calculated as the sum of inventories, trade receivables, trade payables, other current assets, other current liabilities, tax receivables and payables, and accrued income and prepaid expenses. Net Working Capital is not identified as an accounting measure under the applicable accounting standards. The determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore the balance obtained by the Issuer may not be comparable with that determined by the latter. (****) Net Invested Capital is calculated as Net Working Capital, Net Fixed Assets and Non-current Liabilities (which also include deferred and anticipated taxation). Net Invested Capital is not identified as an accounting measure under the applicable accounting standards. The determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore the balance obtained by the Issuer may not be comparable with that determined by the latter.

(***** Net Financial Indebtedness is calculated as the sum of (i) cash and cash equivalents, (ii) financial liabilities, and has been determined in accordance with the provisions of the "Guidelines on disclosure obligations under the Prospectus Regulation" (ESMA32-382-1138) published by ESMA (European Securities and Markets Authority or European Supervisory Authority of financial instruments and markets).

INVESTMENT HIGHLIGHTS



KEY TAKEAWAYS

9M26

Main achievements:

SBU Imaging:

- Consolidated client base in Puglia
- GE HealthCare agreement renewed (to January 2029)

SBU People Support:

- Revenue and margin growth thanks to the broader offering

SBU Mistral:

- Asthma clinical trial completed
- VOCs collaboration in cardiac surgery (Foggia)
- New studies launched (occupational medicine, RECAP)
- STEP project (R.E.S.P.I.R.A) launched

SBU Digital Healthcare:

- Tele-ultrasound platform at Niguarda
- Collaboration with Buzzi Hospital on pediatric tele-ultrasound
- Weatecho network contract
- OPTIP bodycam for ASL Foggia
- Robocore distribution agreement
- Hermes robot at Casa Sollievo della Sofferenza

4Q26
& 2027

In the next months Predict will focus on:

SBU Imaging:

- Consolidating the collaboration with GE HealthCare
- Wider product range and possible extension to neighboring areas

SBU People Support:

- Workforce strengthening and establishment of new products/services

SBU Mistral:

- Filing of new patents
- Development of disease-specific AI algorithms
- Collaboration agreements with pharma companies
- Partnership with Luso Electronics (UK)
- Dialogue with TTOs for partnerships to accelerate validation

SBU Digital Healthcare:

- Intensified commercial and demo activity
- Awaiting outcome of pending procedures and emergency-sector focus
- Development of Optip Nuva (AI-assisted ultrasound)
- Continuation of CURES

PREDICT ON EGM

Market data

IDENTIFIERS & STOCK

Stock code	PRE
ISIN Ordinary Shares	IT0005611071
N. Ordinary Shares	5,869,000
N. Multiple voting shares ¹	1,800,000
N. PAS ²	60,000

IPO DATA

Start date of trading	30/09/2024
Capital raised in IPO (pre greenshoe)	€ 1,519,500
Admission price	€ 1.00
IPO capitalization (ordinary shares)	€ 5,419,500
Euronext Growth Advisor / Specialist	Integrae SIM

DATA AS OF 30/09/2026

Price	€ 1.01
Capitalization (ordinary shares)	€ 5,927,690

Analyst Coverage

Integrae SIM	TP: €1.20
07/10/2026	Rating: BUY



¹ Special category shares issued by the Company, not listed on Euronext Growth Milan, which grant the same rights and obligations as Ordinary Shares, except that each carries three voting rights and is converted into Ordinary Shares pursuant to the rules set forth in the corporate bylaws.

² Special category shares issued by the Company, not listed on the Euronext Growth Milan market, which confer the same rights and obligations as Ordinary Shares, except that they are non-transferable and are automatically converted into Ordinary Shares under the terms and conditions set forth in the Company's bylaws.

Source: Borsa Italiana and Factset, data updated as of 30/09/2026




ANNEX




FINANCIAL HIGHLIGHTS FY25 vs FY24 & FY23

Revenue / VoP (€mn)




EBITDA (€mn)


EBITDA% FY25: 10.3%
(vs. 12.2% FY24)




Net Result (€mn)



NFI / NFI Adj. (€mn)



Equity (€mn)



FY2025 vs FY2024 INCOME STATEMENT

Reclassified Income Statement (Euro/000)	31.12.2025	% ^(*)	31.12.2024	% ^(*)	Var. % FY25-FY24
Sales Revenues	7,595	100.0%	6,626	100.0%	14.6%
Increases in fixed assets for internal work	581	7.7%	-	0.0%	n/a
Other revenues and income	697	9.2%	712	10.7%	-2.1%
Value of Production	8,874	116.8%	7,337	110.7%	20.9%
Costs of raw materials, components, consumption and merchandise	(4,736)	-62.4%	(4,245)	-64.1%	11.6%
Cost of services	(1,545)	-20.3%	(1,263)	-19.1%	22.3%
Use of third-party assets	(136)	-1.8%	(112)	-1.7%	21.4%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	101	1.3%	271	4.1%	-62.7%
Personnel Expenses	(1,755)	-23.1%	(1,149)	-17.3%	52.7%
Other operating expenses	(25)	-0.3%	(31)	-0.5%	-19.4%
EBITDA **	779	10.3%	808	12.2%	-3.6%
Depreciations and write-downs	(563)	-7.4%	(294)	-4.4%	91.5%
EBIT ***	216	2.8%	514	7.8%	-58.0%
Financial income	14	0.2%	(39)	-0.6%	>100.0%
EBT	230	3.0%	475	7.2%	-51.6%
Income taxes	(60)	-0.8%	(139)	-2.1%	-56.8%
Net Result	171	2.2%	336	5.1%	-49.1%

(*) Percentage incidences calculated on sales revenues and service revenues. (**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them. (***) EBIT represents the result before income taxes and financial income and charges. EBIT therefore represents the result of operating activities before the remuneration of both third-party and own capital. EBIT is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBIT is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them. (****) EBT represents the result before income taxes and deferred taxation.

FY2025 vs FY2024 SBU INCOME STATEMENT

Imaging

SBU Imaging Income Statement (Data in Euro/000)	31.12.2025	% ^(*)	31.12.2024	% ^(*)	Var. % FY25-FY24
Sales Revenues	5,369	100.0%	5,173	100.0%	3,8%
Increases in fixed assets for internal work	–	0.0%	-	0.0%	n/a
Other revenues and income	78	1.4%	23	0.4%	> 100,0%
Value of Production	5,447	101.4%	5,197	100.4%	4,8%
Costs of raw materials, components, consumption and merchandise	(3,567)	-66.4%	(3,660)	-70.7%	-2.5%
Cost of services	(503)	-9.4%	(431)	-8.3%	16.7%
Use of third-party assets	(40)	-0.7%	(26)	-0.5%	53.8%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	41	0.8%	244	4.7%	-83.2%
Personnel Expenses	(398)	-7.4%	(254)	-4.9%	56.7%
Other operating expenses	(7)	-0.1%	(19)	-0.4%	-63.2%
EBITDA**	973	18.1%	1.051	20.3%	-7.4%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

FY2025 vs FY2024 SBU INCOME STATEMENT

People Support

SBU People Support Income Statement (Data in Euro/000)	31.12.2025	% ^(*)	31.12.2024	% ^(*)	Var. % FY25-FY24
Sales Revenues	1,151	100.0%	905	100.0%	27.2%
Increases in fixed assets for internal work	–	0.0%	-	0.0%	n/a
Other revenues and income	17	1.5%	5	0,5%	>100.0%
Value of Production	1.168	101.5%	910	100.5%	28.4%
Costs of raw materials, components, consumption and merchandise	(554)	-48.1%	(361)	-39.9%	53.5%
Cost of services	(172)	-14.9%	(110)	-12.1%	56.4%
Use of third-party assets	(21)	-1.9%	(17)	-1.9%	23.5%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	33	2.9%	19	2.1%	73.7%
Personnel Expenses	(272)	-23.7%	(182)	-20.1%	49.5%
Other operating expenses	(4)	-0.3%	(5)	-0.5%	-20.0%
EBITDA **	178	15.5%	254	28.1%	-29.9%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

FY2025 vs FY2024 SBU INCOME STATEMENT

Mistral

SBU Mistral Income Statement (Data in Euro/000)	31.12.2025	% ^(*)	31.12.2024	% ^(*)	Var. % FY25-FY24
Sales Revenues	242	100.0%	258	100.0%	-6.2%
Increases in fixed assets for internal work	360	148.8%	-	0.0%	n/a
Other revenues and income	269	111.0%	421	163.5%	-36.1%
Value of Production	870	359.7%	679	263.5%	28.1%
Costs of raw materials, components, consumption and merchandise	(96)	-39.8%	(76)	-29.6%	26.3%
Cost of services	(441)	-182.3%	(341)	-132.2%	29.3%
Use of third-party assets	(37)	-15.1%	(32)	-12.4%	15.6%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	(0)	-0.1%	(0)	0.0%	n/a
Personnel Expenses	(639)	-263.9%	(399)	-154.8%	60.2%
Other operating expenses	(8)	-3.2%	(5)	-1.8%	60.0%
EBITDA **	(350)	-144.7%	(173)	-67.3%	>100.0%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

FY2025 vs FY2024 SBU INCOME STATEMENT

Digital Healthcare

SBU Digital Healthcare Income Statement (Data in Euro/000)	31.12.2025	% ^(*)	31.12.2024	% ^(*)	Var. % FY25-FY24
Sales Revenues	833	100.0%	290	100.0%	> 100.0%
Increases in fixed assets for internal work	221	26.6%	-	0.0%	n/a
Other revenues and income	334	40.1%	263	90.8%	27.0%
Value of Production	1,388	166.7%	552	190.8%	> 100.0%
Costs of raw materials, components, consumption and merchandise	(520)	-62.4%	(147)	-50.9%	> 100.0%
Cost of services	(428)	-51.4%	(380)	-131.1%	12.6%
Use of third-party assets	(38)	-4.5%	(37)	-12.9%	2.7%
Change in inventories of raw materials, subsidiary materials, consumables, and goods	28	3.3%	8	2.8%	> 100.0%
Personnel Expenses	(446)	-53.6%	(314)	-108.3%	42.0%
Other operating expenses	(6)	-0.8%	(4)	-1.3%	50.0%
EBITDA **	(22)	-2.7%	(321)	-110.9%	-93.1%

(*) Percentage incidences calculated on sales revenues and service revenues.

(**) EBITDA represents the result of operating activities before income taxes, financial income and charges, and depreciation and amortization of fixed assets. EBITDA is not identified as an accounting measure under national accounting standards and therefore should not be considered as an alternative measure for evaluating the trend of the Issuer's operating results. Since the composition of EBITDA is not regulated by the applicable accounting standards, the determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore may not be comparable with them.

FY2025 vs FY2024 BALANCE SHEET

Riclassified Balance Sheet (Euro/000)	31.12.2025	% ^(*)	31.12.2024	% ^(*)	Var. %FY25-FY24
Intangible fixed assets	1,052	41.5%	790	39.4%	33.2%
Tangible fixed assets	534	21.1%	563	28.1%	-5.2%
Financial fixed assets	702	27.7%	633	31.6%	10.9%
Net fixed assets **	2,289	90.3%	1,987	99.1%	15.2%
Inventory	943	37.2%	843	42.0%	11.9%
Trade receivables	2,154	85.0%	2,022	100.9%	6.5%
Trade payables	(2,487)	-98.1%	(3,546)	-176.9%	-29.9%
Trade working capital	611	24.1%	(682)	-34.0%	>100.0%
Other current assets	1,314	51.8%	1,472	73.5%	-10.7%
Other current liabilities	(1,606)	-63.3%	(715)	-35.7%	>100.0%
Net Tax receivables and payables	453	17.9%	235	11.7%	92.8%
Accruals and deferred income	(295)	-11.6%	(47)	-2.4%	>100.0%
Net working capital ***	478	18.8%	263	13.1%	81.7%
Termination indemnity/severance pay	(209)	-8.3%	(223)	-11.1%	-6.3%
Provisions for risks and charges	(22)	-0.9%	(22)	-1.1%	-
Net Invested Capital ****	2,535	100.0%	2,004	100.0%	26.5%
Loans from banks	-	-	371	18.5%	-100.0%
Other current financial assets	-	-	-	-	n/a
Cash and cash equivalents	(1,840)	-72.6%	(2,576)	-128.5%	-28.6%
Net financial Indebtedness *****	(1,840)	-72.6%	(2,205)	-110.0%	-16.6%
Integrated Incentive Program (PIA) contribution	(202)	-8.0%	(1,009)	-50.3%	-80.0%
Financial receivables from Evholo	-	-	(38)	-1.9%	-100.0%
Net financial Indebtedness Adjusted	(2,041)	-80.5%	(3,251)	-162.2%	-37.2%
Share capital	135	5.3%	130	6.5%	3.8%
Reserves and retained earnings	2,580	101.8%	2,254	112.4%	14.5%
Share Premium Reserve	1,489	58.7%	1,489	74.3%	-
Net profit	171	6.7%	336	16.8%	-49.1%
Equity	4,375	172.6%	4,209	210.0%	3.9%
Total sources	2,535	100.0%	2,004	100.0%	26.5%

(*) Percentage incidences calculated on Net Working Capital, deferred/anticipated items and other non-current assets. (**) Net Fixed Assets is calculated as intangible, tangible and financial fixed assets. (***) Net Working Capital is calculated as the sum of inventories, trade receivables, trade payables, other current assets, other current liabilities, tax receivables and payables, and accrued income and prepaid expenses. Net Working Capital is not identified as an accounting measure under the applicable accounting standards. The determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore the balance obtained by the Issuer may not be comparable with that determined by the latter. (****) Net Invested Capital is calculated as Net Working Capital, Net Fixed Assets and Non-current Liabilities (which also include deferred and anticipated taxation). Net Invested Capital is not identified as an accounting measure under the applicable accounting standards. The determination criterion applied by the Issuer may not be homogeneous with that adopted by other companies and therefore the balance obtained by the Issuer may not be comparable with that determined by the latter.

(*****). Net Financial Indebtedness is calculated as the sum of (i) cash and cash equivalents, (ii) financial liabilities, and has been determined in accordance with the provisions of the "Guidelines on disclosure obligations under the Prospectus Regulation" (ESMA32-382-1138) published by ESMA (European Securities and Markets Authority or European Supervisory Authority of financial instruments and markets).

VIDEOS



SUPPLY OF TECHNOLOGIES FOR BREATH ANALYSIS



CONSTRUCTION OF “TURNKEY” BREATH ANALYSIS LABORATORIES



SUPPLY OF AR TECHNOLOGIES FOR TELE-ULTRASOUND



SUPPLY OF AR TECHNOLOGIES FOR EDUCATION AND TRAINING



SUPPLY OF HUMANOID ROBOTS FOR THE DEPARTMENT



PREDICT SITE



MISTRAL LAB

MARKETING MIX

		Imaging	People Support	Mistral	Digital Healthcare
Promotion	- Personal selling	✓	✓	✗	✓
	- Industry trade fairs	✓	✓	✓	✓
	- Websites	✓	✓	✓	✓
	- Dissemination	✗	✗	✓	✗
Placement	- Direct sale	✓	✓	✓	✓
	- Public Tenders	✓	✓	✓	✗
	- Specialized sellers	✗	✗	✗	✓
Pricing	- Distribution policies Price lists	✓	✗	✗	✗
	- Tailor made / Customized	✗	✓	✓	✗
	- Fixed+renewal / Value-based	✗	✗	✗	✓

DISCLAIMER

This document has been prepared by Predict S.p.A. (the "Company") for informational purposes only. It contains only summarized information and, therefore, is of a preliminary nature. Additionally, it has been prepared without claiming to be exhaustive. This presentation ("Presentation") and the information contained therein ("Information"), unless with the prior written consent of the Company, may not be used by the recipient for any purpose, nor may they be disclosed, copied, recorded, transmitted, further distributed to any other person, or published, in whole or in part, by any means or in any form and for any purpose. This presentation may contain financial information and/or operational data and/or market information regarding the business and activities of the Company and its subsidiaries. THIS PRESENTATION AND ANY RELATED ORAL DISCUSSIONS DO NOT CONSTITUTE A PUBLIC OFFERING OR AN INVITATION TO SUBSCRIBE TO, PURCHASE, OR OTHERWISE ACQUIRE FINANCIAL PRODUCTS AS REFERRED TO IN ARTICLE 1, PARAGRAPH 1, LETTER (T) OF LEGISLATIVE DECREE NO. 58 OF 24 FEBRUARY 1998, AS AMENDED. Therefore, this document is not an advertisement and does not in any way constitute a proposal to execute a contract, an offer, or an invitation to purchase, subscribe to, or sell securities, and neither it nor any part of it constitutes the basis on which to rely in relation to any contract or commitment or investment decision. The Company has not prepared and will not prepare any prospectus for the purpose of the initial public offering of securities. Any decision to purchase, subscribe to, or sell securities shall be made independently of this Presentation. Therefore, no provision of this Presentation shall create any binding obligation or liability for the Company and its affiliates and their advisors or representatives. Likewise, the presentation is not intended for distribution in the United States of America, Canada, Australia, Japan, or any jurisdiction where such distribution is unlawful (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "Securities Act")). Neither this Presentation nor any copy of it may be taken or transmitted into the United States of America, its territories or possessions, or distributed, directly or indirectly, in the United States of America, its territories or possessions, or to any U.S. person. Failure to comply with this restriction may constitute a violation of U.S. securities laws. No statement or warranty, express or implied, is or will be given by the Company as to the accuracy, completeness, or correctness of the information provided, and, to the extent permitted by law and except in the case of fraud by the interested party, no liability is accepted for the accuracy or sufficiency thereof, or for errors, omissions, or inaccuracies, negligence, or otherwise, in relation thereto. In particular, but without limitation, no statement or warranty, express or implied, is or will be given as to the achievement or reasonableness of, and no reliance may be placed for any purpose on, the accuracy or completeness of estimates, objectives, projections, or forecasts and nothing in these materials should be considered as a promise or representation for the future. The information and opinions contained in this document are provided as of the date of this document and are subject to change without notice. The recipient will be solely responsible for its own assessment of the information contained in the Presentation. Neither the Company and its affiliates, nor their advisors or representatives shall be obliged to provide or update any information or to notify or correct any inaccuracies in any information. Neither the Company and its affiliates, nor any of their advisors or representatives shall have any liability to the recipient or any of its representatives as a result of the use or reliance on the information contained in this document. Some information may contain forward-looking statements that involve risks and uncertainties and are subject to change. In some cases, these forward-looking statements may be identified by the use of words such as "believe," "anticipate," "estimate," "target," "potential," "expect," "predict," "forecast," "project," "may," "should," "could," "shall," "will," "plan," "intend," "seek," and similar expressions. The forecasts and forward-looking statements included in this document are necessarily based on a number of assumptions and estimates that are inherently subject to significant economic, operational, economic, and competitive uncertainties and unforeseen events, as well as assumptions relating to future business decisions subject to change. By their nature, forward-looking statements involve known and unknown risks and uncertainties, as they relate to events and depend on circumstances that may or may not occur in the future. Additionally, actual results may substantially differ from those contained in any forward-looking statement due to a number of significant risks and future events that are beyond the control of the Company and cannot be estimated in advance, such as the future economic environment and the actions of competitors and other parties involved in the market. These forward-looking statements speak only as of the date of this presentation. The Company cautions that forward-looking statements are not guarantees of future performance and that its current financial position, business strategy, plans, and management's objectives for future operations may differ materially from those contained or suggested by the forward-looking statements contained in this Presentation. Furthermore, even if the Company's financial position, business strategy, plans, and management's objectives for future operations are consistent with the forward-looking statements contained in this Presentation, such results or developments may not be indicative of results or developments in future periods. The Company expressly disclaims any obligation or commitment to disclose updates or revisions to any forward-looking statement contained herein to reflect any change in the Company's expectations in relation thereto or any change in events, conditions, or circumstances on which such statement is based. By receiving this Presentation, the user acknowledges and agrees to be bound by the above terms, conditions, limitations, and restrictions.

In case of any discrepancies or differences in interpretation between the Italian and English versions of the presentation, the Italian version shall prevail and be considered the most reliable.



PREDICT

Bari

Viale Adriatico, 4 c/o Fiera del Levante - Pad. 105 | +39 080 893 3754

Milano

Piazza Gae Aulenti 1, Torre B | +39 02 9713 0325

Roma

Via Marsala 29H | +39 06 4547 3124

predictcare.it

INVESTOR RELATIONS MANAGER

Angelo Ceci, CFO & IRM - Predict

E-mail: investor.relator@predictcare.it

Tel. +39 080 893 3754

INVESTOR RELATIONS ADVISOR

Chiara Cardelli, Senior Associate - KT&Partners

E-mail: ccardelli@ktepartners.com

Tel. +39 3387129015